Max Foundation and BeiGene to provide Free Brukinsa to 29 LMICs
May 17, 2023
The Max Foundation, a Seattle-based organization dedicated to health equity, is collaborating with the biotech BioGene to provide Brukinsa to patients with chronic lymphocytic leukemia (CLL) in 29 lower- and middle-income countries (LMICs). The program will last for 3 years and will also provide education on disease management and diagnosis at participating treatment sites.
According to Angus Liu, “To help fund Max’s operations, BeiGene will also offer a grant from the BeiGene Foundation. The company said it will explore potentially expanding the partnership beyond the initial three-year term. No matter what it eventually decides, patients who have received Brukinsa under this program will continue to receive the drug, a BeiGene spokesperson said.”
To read more, click here.
(Source: Fierce Pharma, May 17th, 2023)